Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.25 +1.2%	$0.27	$0.20 ▼ $1.48	$64.94M	2.24	1.67 million shs	936,666 shs
NICXF Nicox	$0.25	$0.25	$0.25 ▼ $0.28	$17.23M	0.29	N/A	N/A
SKYE Skye Bioscience	$4.11 -3.3%	$2.38	$1.14 ▼ $9.58	$127.33M	1.69	477,791 shs	7.48 million shs
STRO Sutro Biopharma	$0.73 -8.1%	$0.88	$0.52 ▼ $5.17	$61.99M	1.7	1.13 million shs	11.76 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	0.00%	-3.16%	-7.55%	+24.37%	-74.87%
NICXF Nicox	0.00%	0.00%	0.00%	0.00%	-43.18%
SKYE Skye Bioscience	0.00%	+90.28%	+105.71%	+158.00%	-48.69%
STRO Sutro Biopharma	0.00%	-8.35%	-18.63%	+12.82%	-74.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	3.237 of 5 stars	4.1	5.0	0.0	0.0	2.3	0.8	0.0
NICXF Nicox	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	2.3868 of 5 stars	3.5	4.0	0.0	0.0	3.2	0.0	0.0
STRO Sutro Biopharma	3.7166 of 5 stars	3.1	1.0	0.0	4.7	3.3	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.29	Hold	$1.35	451.70% Upside
NICXF Nicox	0.00	N/A	N/A	N/A
SKYE Skye Bioscience	3.00	Buy	$16.60	303.89% Upside
STRO Sutro Biopharma	2.25	Hold	$6.11	733.01% Upside

Current Analyst Ratings Breakdown

Latest NICXF, ADAP, STRO, and SKYE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ADAP Adaptimmune Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$1.50 ➝ $0.50
6/24/2025	SKYE Skye Bioscience	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
6/16/2025	STRO Sutro Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$2.00
5/20/2025	SKYE Skye Bioscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/19/2025	STRO Sutro Biopharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$1.00 ➝ $0.80
5/14/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$1.50 ➝ $1.00
5/14/2025	ADAP Adaptimmune Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$1.00 ➝ $0.46
4/29/2025	STRO Sutro Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$2.00 ➝ $2.00
4/11/2025	ADAP Adaptimmune Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/1/2025	ADAP Adaptimmune Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.50 ➝ $3.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$178.03M	0.36	N/A	N/A	$0.05 per share	4.90
NICXF Nicox	$5.52M	3.12	N/A	N/A	N/A	∞
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	$2.25 per share	N/A
STRO Sutro Biopharma	$62.04M	1.00	N/A	N/A	$0.54 per share	1.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$70.81M	-$0.27	N/A	N/A	N/A	-38.91%	-163.73%	-23.65%	8/11/2025 (Estimated)
NICXF Nicox	-$29.25M	N/A	0.00	∞	N/A	N/A	N/A	N/A	7/16/2025 (Estimated)
SKYE Skye Bioscience	-$26.57M	-$0.82	N/A	N/A	N/A	N/A	-53.92%	-48.58%	N/A
STRO Sutro Biopharma	-$227.46M	-$2.98	N/A	N/A	N/A	-373.66%	-347.60%	-59.46%	8/12/2025 (Estimated)

Latest NICXF, ADAP, STRO, and SKYE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.18	-$0.18	N/A	-$0.18	$6.55 million	$7.29 million
5/8/2025	Q1 2025	SKYE Skye Bioscience	-$0.31	-$0.28	+$0.03	-$0.28	N/A	N/A
5/8/2025	Q1 2025	STRO Sutro Biopharma	-$0.63	-$0.91	-$0.28	-$0.91	$11.61 million	$17.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
NICXF Nicox	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A
STRO Sutro Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	4.24	2.02	1.79
NICXF Nicox	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	11.85	11.85
STRO Sutro Biopharma	N/A	2.16	2.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
NICXF Nicox	N/A
SKYE Skye Bioscience	21.09%
STRO Sutro Biopharma	96.99%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.44%
NICXF Nicox	N/A
SKYE Skye Bioscience	3.00%
STRO Sutro Biopharma	5.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	232.08 million	Optionable
NICXF Nicox	28	68.92 million	N/A	Not Optionable
SKYE Skye Bioscience	11	30.98 million	30.05 million	Optionable
STRO Sutro Biopharma	240	84.46 million	79.48 million	Optionable

NICXF, ADAP, STRO, and SKYE Headlines

Recent News About These Companies

Sutro Biopharma (NASDAQ:STRO) Upgraded by Piper Sandler to Overweight Rating

June 16, 2025 | marketbeat.com

Sutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of "Hold" by Analysts

June 16, 2025 | marketbeat.com

Sutro Biopharma upgraded to Overweight from Neutral at Piper Sandler

June 16, 2025 | msn.com

Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Millennium Management LLC

June 7, 2025 | marketbeat.com

Sutro Biopharma, Inc. (NASDAQ:STRO) Short Interest Update

June 3, 2025 | marketbeat.com

Sutro Biopharma Appoints Greg Chow as Chief Financial Officer

June 2, 2025 | finance.yahoo.com

Sutro Biopharma, Inc.: Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

May 9, 2025 | finanznachrichten.de

Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

May 8, 2025 | globenewswire.com

Sutro Biopharma to Participate in Upcoming Investor Conferences

May 1, 2025 | globenewswire.com

Why Sutro Biopharma, Inc.’s (STRO) Stock Is Down 21.92%

April 26, 2025 | aaii.comA

Why Sutro Biopharma, Inc.’s (STRO) Stock Is Down 10.88%

April 1, 2025 | aaii.comA

Why Sutro Biopharma, Inc.’s (STRO) Stock Is Up 15.10%

March 18, 2025 | aaii.comA

Sutro Biopharma downgraded to Neutral from Buy at H.C. Wainwright

March 17, 2025 | markets.businessinsider.com

HC Wainwright & Co. Downgrades Sutro Biopharma (STRO)

March 17, 2025 | msn.com

Sutro Biopharma presents expanded data from REFRalphaME-01 trial

March 16, 2025 | markets.businessinsider.com

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

March 15, 2025 | tmcnet.com

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

March 15, 2025 | tmcnet.com

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

March 15, 2025 | globenewswire.com

Why Sutro Biopharma, Inc.’s (STRO) Stock Is Down 35.19%

March 15, 2025 | aaii.comA

Wedbush Downgrades Sutro Biopharma (STRO)

March 15, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
3 Top-Rated Energy Companies Staging Strong Recoveries
By Nathan Reiff | June 2, 2025
View 3 Top-Rated Energy Companies Staging Strong Recoveries
Chime’s Smart IPO: Half the Valuation, Double the Strength
By Jeffrey Neal Johnson | June 18, 2025
View Chime’s Smart IPO: Half the Valuation, Double the Strength
Super Micro Computer Stock's Rally Backed by Strong Financials
By Gabriel Osorio-Mazilli | June 19, 2025
View Super Micro Computer Stock's Rally Backed by Strong Financials
These 3 Dividend Stocks Combine Strong Yields With Upside
By Chris Markoch | June 20, 2025
View These 3 Dividend Stocks Combine Strong Yields With Upside

NICXF, ADAP, STRO, and SKYE Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.24 +0.00 (+1.16%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.25 +0.00 (+1.22%)

As of 04:57 AM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Nicox OTCMKTS:NICXF

$0.25 0.00 (0.00%)

As of 06/27/2025

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France.

Skye Bioscience NASDAQ:SKYE

$4.11 -0.14 (-3.29%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.27 +0.16 (+3.89%)

As of 05:27 AM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Sutro Biopharma NASDAQ:STRO

$0.73 -0.07 (-8.14%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.74 +0.01 (+0.82%)

As of 04:02 AM Eastern

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time